Shifting patterns of inhaled antibiotic use in cystic fibrosis

被引:48
|
作者
Moskowitz, Samuel M. [1 ]
Silva, Stefanie J. [2 ]
Mayer-Hamblett, Nicole [1 ]
Pasta, David J. [2 ]
Mink, David R. [2 ]
Mabie, Jenny A. [3 ]
Konstan, Michael W. [4 ]
Wagener, Jeffrey S. [3 ,5 ]
机构
[1] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA
[2] ICON Clin Res, San Francisco, CA USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA
[5] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA
关键词
cystic fibrosis; Pseudomonas aeruginosa; airway infection; antibiotics; tobramycin; colistin; inhaled therapy; epidemiology;
D O I
10.1002/ppul.20873
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Rationale: Antibiotic inhalation has become widely accepted as a standard treatment for cystic fibrosis (CF) airway infection. We assessed the prevalence and context of inhaled antibiotic use in the North American CIF population. Our working hypothesis was that a shift from acute to chronic use of inhaled antibiotics has coincided with increased prevalence of use among CF patients. Methods: Descriptive statistics were collected for 30,833 patients enrolled in the Epidemiologic Study of CF (ESCF) during 1996 through 2005. A multivariate analysis was performed on data from a subgroup of 18,021 patients enrolled in ESCF during 2003 through 2005. Results: The prevalence of inhaled antibiotic use in the North American CF population increased during 1996 through 2005 due to increased chronic use, while acute use to treat pulmonary exacerbations decreased. In 2005, 50% of CF patients used inhaled tobramycin and 9% used inhaled colistin chronically; most of the latter used both agents concurrently Airway obstruction severity and airway infection status were predictors of inhaled antibiotic use. Conclusions: Increased chronic use and decreased acute use of inhaled antibiotics presumably reflect a shift toward more proactive management of airway infections in the North American CIF population. The effects of these usage patterns on long-term clinical outcomes and emergence of antibiotic-resistant Pseudomonas aeruginosa strains warrant further study.
引用
收藏
页码:874 / 881
页数:8
相关论文
共 50 条
  • [41] Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres
    Smith, Daniel J.
    Ramsay, Kay A.
    Yerkovich, Stephanie T.
    Reid, David W.
    Wainwright, Claire E.
    Grimwood, Keith
    Bell, Scott C.
    Kidd, Timothy J.
    RESPIROLOGY, 2016, 21 (02) : 329 - 337
  • [42] Inhaled corticosteroids and Aspergillus fumigatus isolation in cystic fibrosis
    Noni, Maria
    Katelari, Anna
    Dimopoulos, George
    Kourlaba, Georgia
    Spoulou, Vana
    Alexandrou-Athanassoulis, Helen
    Doudounakis, Stavros-Eleftherios
    Tzoumaka-Bakoula, Chryssa
    MEDICAL MYCOLOGY, 2014, 52 (07) : 715 - 722
  • [43] The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
    Heirali, Alya A.
    Workentine, Matthew L.
    Acosta, Nicole
    Poonja, Ali
    Storey, Douglas G.
    Somayaji, Ranjani
    Rabin, Harvey R.
    Whelan, Fiona J.
    Surette, Michael G.
    Parkins, Michael D.
    MICROBIOME, 2017, 5
  • [44] Intravenous and Inhaled Antimicrobials at Home in Cystic Fibrosis Patients
    Thigpen, Jim
    Odle, Brian
    HOME HEALTH CARE MANAGEMENT AND PRACTICE, 2014, 26 (02) : 101 - 109
  • [45] Nebulizer choice for inhaled colistin treatment in cystic fibrosis
    Katz, SL
    Ho, SL
    Coates, AL
    CHEST, 2001, 119 (01) : 250 - 255
  • [46] Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis
    Akkerman-Nijland, Anne M.
    Hagedoorn, Paul
    Rottier, Bart L.
    Grasmeijer, Floris
    Frijlink, Henderik W.
    van Luin, Mathijs
    ter Weijden, E.
    Merkus, Peter J.
    Touw, Daan J.
    Akkerman, Onno W.
    Koppelman, Gerard H.
    PHARMACEUTICS, 2025, 17 (03)
  • [47] Sputum Tobramycin Concentrations in Cystic Fibrosis Patients with Repeated Administration of Inhaled Tobramycin
    Ruddy, Jennifer
    Emerson, Julia
    Moss, Richard
    Genatossio, Alan
    McNamara, Sharon
    Burns, Jane L.
    Anderson, Gail
    Rosenfeld, Margaret
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2013, 26 (02) : 69 - 75
  • [48] Inhaled Biologicals for the Treatment of Cystic Fibrosis
    Sala, Valentina
    Murabito, Alessandra
    Ghigo, Alessandra
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2019, 13 (01) : 19 - 26
  • [49] Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
    Moss, RB
    CHEST, 2002, 121 (01) : 55 - 63
  • [50] The problems of antibiotic resistance in cystic fibrosis and solutions
    Lopez-Causape, Carla
    Rojo-Molinero, Estrella
    Macia, Maria D.
    Oliver, Antonio
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (01) : 73 - 88